Novavax to Participate in World Vaccine Congress Europe
PR92370
GAITHERSBURG, Md., Oct. 16, 2021 /PRNewswire=KYODO JBN/ --
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing
and commercializing next-generation vaccines for serious infectious diseases,
today announced that Vivek Shinde, M.D., Vice President, Clinical Development,
will deliver a presentation during the World Vaccine Congress Europe 2021
A topic of discussion will be Novavax' COVID-NanoFlu(TM) Combination
Vaccine, which combines the company's recombinant nanoparticle protein-based
COVID-19 and NanoFlu(TM) vaccine candidates with Matrix-M(TM) adjuvant in a
single formulation.
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
Session details are as follows:
Date: Wednesday, October 20, 2021
Time: 11:30 a.m. -- 12:00 p.m. Central European Time (CET) / 5:30 a.m. --
6:00 a.m. Eastern Daylight Time (EDT)
Title: Update on Novavax' NanoFlu vaccine and COVID-19-NanoFlu Combination
Vaccine development
Novavax Participant: Vivek Shinde, M.D., Vice President, Clinical Development
For more information or to register, visit the Congress website
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved
health globally through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The company's
proprietary recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. Novavax is conducting
late-stage clinical trials for NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19. NanoFlu(TM), its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase
3 clinical trial in older adults. Both vaccine candidates incorporate Novavax'
proprietary saponin-based Matrix-M(TM) adjuvant to enhance the immune response
and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on
Twitter (https://c212.net/c/link/?t=0&l=en&o=3325009-1&h=2072522266&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3158017-1%26h%3D500821283%26u%3Dhttps%253A%252F%252Ftwitter.com%252FNovavax%26a%3DTwitter&a=Twitter) and LinkedIn (https://c212.net/c/link/?t=0&l=en&o=3325009-1&h=1813672409&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3158017-1%26h%3D3702938248%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fnovavax%252F%26a%3DLinkedIn&a=LinkedIn).
Contacts:
Investors
Novavax, Inc.
Erika Schultz | +1 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | +1 617-221-9197
aroy@soleburytrout.com
Media
Ali Chartan | +1 240-720-7804
Laura Keenan Lindsey | +1 202-709-7521
media@novavax.com
SOURCE: Novavax, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。